Revenue Growth
Fourth quarter revenue reached $5.4 million, marking a 14% increase over the fourth quarter of 2023. Full-year revenue for 2024 was $19.6 million, up from $17.3 million in 2023.
Annual Recurring Revenue (ARR) Increase
Total ARR increased to $9.8 million at the end of the fourth quarter of 2024, up from $8.8 million at the end of the fourth quarter of 2023. Subscription ARR increased from $1.7 million to $2.6 million year-over-year.
Successful SaaS Transition
iCAD made significant progress in transitioning to a SaaS-based model, reporting strong cloud adoption with 19 cloud deals in Q4, up from 13 in Q3 and 10 in Q2.
FDA Clearance of ProFound Detection Version 4.0
The new version offers a 22% improvement in detecting aggressive cancers, with a 50% increase in sensitivity for dense breast tissue and a 60% improvement in identifying invasive lobular cancers.
Global Expansion and Partnerships
Signed new distribution agreements in South Africa and Portugal, and a significant deal with Sectra in the UK. Also secured regulatory approval in Jordan.